The patent for Keytruda, a game-changing immunotherapy medication developed by Merck & Co., is set to expire in 2028. This development potentially allows other pharmaceutical companies to create and market their own versions of the drug. This could increase competition, lower prices, and increase patient access to treatment. However, concerns about availability and quality of generic versions arise. The patent expiration also significantly impacts the pharmaceutical industry and the future of immunotherapy.
400+ SAP NetWeaver Devices Vulnerable to 0-Day Attacks that Exploited in the Wild
Shadow Servers have identified 454 vulnerable SAP NetWeaver systems affected by a critical zero-day flaw, CVE-2025-31324, allowing unauthenticated file uploads and potential system compromise. Discovered
